• Eikon Therapeutics flagged seven abstracts accepted for presentation at the 2026 ESMO Congress in Madrid.
• Updates include TeLuRide-005 Phase 2 data for EIK1001 in stage IV NSCLC, including results from the squamous cohort.
• Disclosures also cover Phase 1/2 readouts for EIK1003, EIK1004, and EIK1005 across multiple advanced solid tumor settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.